Skip to content

Optimal Dosage of Remifentanil for Vertebroplasty

Comparison of Two Dosage of Remifentanil Infusion Combined with Propofol-based Total Intravenous Anesthesia in Percutaneous Vertebroplasty

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05876039
Enrollment
80
Registered
2023-05-25
Start date
2023-05-20
Completion date
2024-12-27
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Remifentanil

Keywords

Vertebroplasty, Remifentanil, Target-controlled infusion, Procedural analgesia and sedation

Brief summary

Percutaneous vertebroplasty has become a mainstay in the management of osteoporotic and malignant vertebral fractures. Procedural analgesia and sedation (PAS) with propofol and remifentanil may provides optimal hypnotic and analgesic effects.

Detailed description

Percutaneous vertebroplasty has become a mainstay in the management of osteoporotic and malignant vertebral fractures. Many anesthetic methods have been used in percutaneous vertebroplasty; however, there is no gold-standard method. Procedural analgesia and sedation (PAS) are one of the commonly used approaches. For its unique properties, including rapid onset, precise intraoperative control, and a fast recovery profile, remifentanil is preferable to other opioids administration in a target-controlled infusion (TCI) pump. Combination of remifentanil with propofol may improve sedation experience; however, it can increase a risk of respiratory depression. Moreover, propofol and remifentanil are often administered with 2 TCI pumps to, respectively, provide hypnotic and analgesic effects, which together are considered to be an ideal anesthetic technique.

Interventions

DRUGInitial remifentanil effect-site concentration

Different initial remifentanil effect-site concentration

Sponsors

Tri-Service General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists (ASA) score of I-III patients receiving percutaneous vertebroplasty under procedural sedation and analgesia with remifentanil and propofol

Exclusion criteria

* Age \< 20 or \> 80 years * ASA classifications \> III * Pregnancy * Known allergies to opioids, propofol or any drugs used in the study * Emergency surgery * Patient refusal

Design outcomes

Primary

MeasureTime frameDescription
Adequate analgesia at the time of the trocar needle insertionTime at the trocar needle placementRemaining moveless at the time of the trocar needle insertion
Adequate analgesia at the time of the bone cement injectionTime at the bone cement injectionRemaining moveless at the time of the bone cement injection

Secondary

MeasureTime frameDescription
Apnea with desaturation at the time of the trocar needle placementTime at the trocar needle placementOxygen saturation \< 95%
Apnea with desaturation at the time of the bone cement injectionTime at the bone cement injectionOxygen saturation \< 95%
Hypotension at the time of the trocar needle placementTime at the trocar needle placementMean blood pressure \> 30% decrease from baseline
TCI pump adjustments at the time of the bone cement injectionTime at the bone cement injectionFrequency of TCI pump adjustments
Numeric rating scalePostoperative one hourPostoperative numeric rating scale. NRS scores is labeled from zero to ten, with zero being an example of someone with no pain and ten being the worst pain possible.
TCI pump adjustments at the time of the trocar needle placementTime at the trocar needle placementFrequency of TCI pump adjustments
Hypotension at the time of the bone cement injectionTime at the bone cement injectionMean blood pressure \> 30% decrease from baseline

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026